Waikoloa, Hawaii - Psoriatic patients responding to efalizumab (Raptiva, Genentech Inc. and Xoma Ltd.) biologic medication are happy with the results after an extended period of continuous treatment.
Discovering Dermatology Times: March 2024 Enhancing Psoriasis Management Supplement
ReV Up Your Vitiligo Treatment Strategies
Skin Swab Analysis Reveals Early Predictors of Atopic Dermatitis in Infants
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Reviewing Late-Breaking Research From AAD 2024
A Spotlight on SCIN: A New Tool From Google and Researchers at Stanford Medicine